By Mill Chart
Last update: Oct 31, 2023
Take a closer look at SANOFI-ADR (NASDAQ:SNY), a stock of interest to dividend investors uncovered by our stock screener. NASDAQ:SNY excels in fundamentals and provides a decent dividend, all while maintaining a reasonable valuation. Let's break it down further.
ChartMill assigns a proprietary Dividend Rating to each stock. The score is computed by evaluating various valuation aspects, like the yield, the history, the dividend growth and sustainability. NASDAQ:SNY was assigned a score of 8 for dividend:
Every stock is evaluated by ChartMill, receiving a Health Rating on a scale of 0 to 10. This assessment considers different health aspects, including liquidity and solvency, both in absolute terms and relative to industry peers. NASDAQ:SNY has achieved a 7 out of 10:
ChartMill utilizes a Profitability Rating to assess stocks, scoring them on a scale of 0 to 10. This rating takes into account a variety of profitability ratios and margins, both in absolute terms and in comparison to industry peers. NASDAQ:SNY has earned a 8 out of 10:
More Best Dividend stocks can be found in our Best Dividend screener.
Our latest full fundamental report of SNY contains the most current fundamental analsysis.
This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.
SANOFI-ADR
NASDAQ:SNY (4/26/2024, 7:16:56 PM)
After market: 49.13 0 (0%)49.13
-0.23 (-0.47%)
/PRNewswire/ -- SobiĀ® today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion...
SNY earnings call for the period ending March 31, 2024.
SNY stock results show that Sanofi beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
AstraZeneca soundly topped analyst views while Sanofi narrowed its losses. Both stocks surged in early trade.
Vertex hopes Alpine's drug can be tested on other conditions beyond the one entering Phase 3 trial for a kidney disease.
Auddia stock is taking off on Monday with heavy trading of AUUD stock after the company received a new AI tech patent.
Apartment Income REIT stock is rising higher on Monday as investors in AIRC shares react to a deal to take the company private.